Overview

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

Status:
Recruiting

Trial end date:
2023-06-30

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2 dose (RP2D) and schedule of pamiparib in combination with TMZ, and to determine the antitumor activity of pamiparib in combination with TMZ.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

BeiGene
BeiGene USA, Inc.

Collaborator:

Myriad Genetics, Inc.

Treatments:

Dacarbazine
Poly(ADP-ribose) Polymerase Inhibitors
Temozolomide